%PDF-1.4
%
36 0 obj
<>
endobj
33 0 obj
<>
endobj
77 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-02-05T16:05:21Z
2024-03-28T10:14:52-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-28T10:14:52-07:00
application/pdf
Heather
2003-231.march
uuid:713c85b7-1dd2-11b2-0a00-8a0827bd7700
uuid:713c85ba-1dd2-11b2-0a00-900000000000
endstream
endobj
22 0 obj
<>
endobj
23 0 obj
<>
endobj
37 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 12 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 14 0 R/Type/Page>>
endobj
4 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 16 0 R/Type/Page>>
endobj
87 0 obj
[91 0 R]
endobj
88 0 obj
<>stream
q
0 0 612 792 re
W n
BT
0.8 g
/T1_0 18 Tf
0.6114 0.7912 -0.7912 0.6114 35.383 35.2215 Tm
(Personal, non-commercial use only. The Journal of Rheumatology. Copyrigh\
t \251 2004. All rights reserved.)Tj
ET
Q
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
0 0 0 1 K
/GS1 gs
54 54 m
558 54 l
S
BT
0 0 0 1 k
/T1_1 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 424.3613 35.9844 Tm
(The Journal of Rheumatology 2004; 31:3)Tj
0 Tc 0 Tw -46.2952 -0.0313 Td
(600)Tj
ET
0 0 0 0 k
/GS0 gs
109.25 59.09 396.47 -10.83 re
f*
0.5 w
109.25 59.09 396.47 -10.83 re
S
BT
0 0 0 1 k
/GS1 gs
/T1_2 1 Tf
-0.00011 Tc -0.02119 Tw 10 0 0 10 54 713.1616 Tm
[(hypoxemia in SCD correlates with increased CD1)36.8 (1b expres-)]TJ
0.0042 Tc 0.3707 Tw 0 -1.2 TD
(sion on monocytes and neutrophils and with platelet-)Tj
-0.00011 Tc 0.04939 Tw T*
(erythrocyte complex formation)Tj
0 Tc 0 Tw 6.5 0 0 6.5 179.3776 692.4616 Tm
(12)Tj
-0.00011 Tc 0.04939 Tw 10 0 0 10 185.8775 689.1616 Tm
(, suggesting an association)Tj
0.24071 Tw -13.1877 -1.2 Td
(between oxygen saturation, inflammatory cell activation,)Tj
0.02499 Tw T*
(and adhesiveness in SCD.)Tj
0.01131 Tc 0.3636 Tw 1.2 -1.2 Td
(An inflammatory component is suggested in some)Tj
-0.00011 Tc 0.1087 Tw -1.2 -1.2 Td
(patients with FM: levels of interleukin \(IL\)-1Ra, and IL-8)Tj
0.0553 Tw T*
(were significantly higher in FM sera than in controls)Tj
0 Tc 0 Tw 6.5 0 0 6.5 268.9051 632.4615 Tm
(13)Tj
-0.0002 Tc 0.0553 Tw 10 0 0 10 275.4051 629.1616 Tm
(; IL-)Tj
-0.00011 Tc 0.09081 Tw -22.1405 -1.2 Td
[(1\247, IL-6, and tumor necrosis factor)19.7 (-)]TJ
/T1_3 1 Tf
0 Tc 0 Tw [-0.4 (\002)]TJ
/T1_2 1 Tf
-0.00011 Tc 0.09081 Tw 15.7046 0 Td
(were detected in the)Tj
0.2075 Tw -15.7046 -1.2 Td
(skin of 30% of FM patients, but in none of the healthy)Tj
0 Tw T*
(controls)Tj
0 Tc 6.5 0 0 6.5 86.2119 596.4615 Tm
(14)Tj
10 0 0 10 92.7118 593.1616 Tm
(.)Tj
-0.00011 Tc 0.2265 Tw -2.6712 -1.2 Td
[(A)91.8 (wareness of the high frequency of FM in SCD can)]TJ
-0.01759 Tw -1.2 -1.2 Td
(improve the treatment of pain during sickle cell crisis. Some)Tj
0.0455 Tw T*
(of the pain that is labeled as sickle cell crisis pain is due to)Tj
0.0152 Tw T*
[(FM and improves with tender point injections. )17.8 (T)69.9 (ender point)]TJ
0.14461 Tw T*
[(injections are part of the treatment of FM. )17.6 (There are few)]TJ
0.0274 Tw T*
(well-controlled studies)Tj
0 Tc 0 Tw 6.5 0 0 6.5 145.6293 524.4616 Tm
(15)Tj
-0.00011 Tc 0.0274 Tw 10 0 0 10 152.1293 521.1616 Tm
[(. )54.8 (A)-222.5 (variety of substances have been)]TJ
-0.0092 Tw -9.8129 -1.2 Td
[(found to be ef)17.7 (fective. )17.7 (The nature of the injected substance is)]TJ
0.0181 Tw T*
(not a critical factor)Tj
0 Tc 0 Tw 6.5 0 0 6.5 130.329 500.4616 Tm
(15)Tj
-0.00011 Tc 0.0182 Tw 10 0 0 10 136.829 497.1616 Tm
[(. In this study)64.8 (, methylprednisolone was)]TJ
0.0256 Tw -8.2829 -1.2 Td
(used in the tender point injections, since there was question)Tj
0.01669 Tc 0.3582 Tw T*
(of chronic inflammation contributing to sickling and)Tj
-0.00011 Tc 0.02499 Tw T*
(possibly to FM in the SCD patients.)Tj
0.0199 Tc 0.4124 Tw 1.2 -1.2 Td
[(Lar)17.7 (ge prospective randomized controlled trials of)]TJ
-0.00011 Tc 0.0117 Tw -1.2 -1.2 Td
(patients with stable chronic SCD as well as SCD patients in)Tj
0.1525 Tw T*
(crisis are needed to further evaluate whether FM is more)Tj
0.0968 Tw T*
(prevalent in SCD compared to age, race, and sex matched)Tj
0.12219 Tw T*
(patients with anemia. Insight into the pathogenesis of FM)Tj
0.0341 Tw T*
(may be gained by better understanding the causes of FM in)Tj
0 Tw T*
(SCD.)Tj
/T1_4 1 Tf
0 -2.4 TD
(ACKNOWLEDGMENT)Tj
/T1_2 1 Tf
0.0705 Tw 8 0 0 8 54 343.1616 Tm
[(The author is grateful to Drs. Jonathan Harrison, Mala )17.8 (V)110.8 (arma, and )17.8 (V)59.8 (ictor)]TJ
0.05901 Tw 0 -1.25 TD
(Chang from the Division of Hematology at UMDNJ for their requests for)Tj
0.0844 Tw T*
[(consultations, and also thanks Dr)54.8 (. Michael Schlesinger for reviewing this)]TJ
0 Tw T*
(manuscript.)Tj
/T1_4 1 Tf
10 0 0 10 318 713.1616 Tm
(REFERENCES)Tj
/T1_2 1 Tf
0.02499 Tw 8 0 0 8 325 703.1616 Tm
[(1.)-875.1 (W)79.9 (olfe F)79.7 (, Smythe HA, )36.8 (Y)110.8 (unus MB, et al. )17.7 (The )54.8 (American College of)]TJ
1.675 -1.25 Td
(Rheumatology 1990 criteria for the classification of fibromyalgia.)Tj
T*
[(Report of the Multicenter Criteria Committee. )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(1990;33:160-72. )Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(2.)-875.1 (Bennet RM. )17.7 (The rational management of fibromyalgia patients.)]TJ
1.675 -1.25 Td
[(Rheum Dis Clin North )54.8 (Am 2002;28:181-99.)]TJ
-1.675 -1.25 Td
[(3.)-875.1 (Bor)17.7 (g-Stein J. Management of peripheral pain generators in)]TJ
1.675 -1.25 Td
[(fibromyalgia. Rheum Dis Clin North )54.8 (Am 2002;28:305-17.)]TJ
-1.675 -1.25 Td
[(4.)-875.1 (Castele RJ, Strohl KP)110.7 (, Chester S, Brittenham GM, Harris JW)91.7 (.)]TJ
1.675 -1.25 Td
(Oxygen saturation with sleep in patients with sickle cell disease.)Tj
T*
(Arch Intern Med 1986;146:722-25.)Tj
-1.675 -1.25 Td
[(5.)-875.1 (Kirkham FJ, Hewes DK, Pregler M, )17.7 (W)79.9 (ade )54.8 (A, Lane R, Evans JP)110.7 (.)]TJ
1.675 -1.25 Td
(Nocturnal hypoxaemia and central-nervous-system events in )Tj
T*
(sickle-cell disease. Lancet 2001;357:1656-9.)Tj
-1.675 -1.25 Td
[(6.)-875.1 (Scharf MB, Lobel JS, Caldwell E. Nocturnal oxygen desaturation in)]TJ
1.675 -1.25 Td
[(sickle cell anemia [letter]. JAMA)-220.2 (1983;250:2789-90.)]TJ
-1.675 -1.25 Td
[(7.)-875.1 (Simms R)54.8 (W)91.8 (. Is there muscle pathology in fibromyalgia syndrome?)]TJ
1.675 -1.25 Td
[(Rheum Dis Clin North )54.8 (Am 1996;22:245-66.)]TJ
-1.675 -1.25 Td
[(8.)-875.1 (Hoover R, Rubin R, )17.7 (W)39.8 (ise G, )17.7 (W)79.9 (arren, R. )54.8 (Adhesion of normal and)]TJ
1.675 -1.25 Td
(sickle erythrocytes to endothelial monolayer cultures. Blood)Tj
0 Tc 0 Tw T*
(1979;54:872-6. )Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(9.)-875.1 (Lard LR, Mul FP)110.7 (, de-Haas M, Roos D, Duits )54.8 (AJ. Neutrophil )]TJ
1.675 -1.25 Td
[(activation in sickle cell disease. J Leukocyte Biol 1999;66:41)36.8 (1-5.)]TJ
-2.175 -1.25 Td
[(10.)-875.1 (W)39.8 (un )17.7 (T)74 (, Paglieroni )17.7 (T)74 (, Rangaswami )54.8 (A, et al. Platelet activation in)]TJ
2.175 -1.25 Td
(patients with sickle cell disease. Br J Haematol 1998;100:741-9.)Tj
-2.1381 -1.25 Td
[(1)36.8 (1)-0.1 (.)-875.1 (Solovey )54.8 (A, Lin )36.8 (Y)128.9 (, Browne P)110.7 (,)-0.1 ( Choong S, )17.7 (W)79.9 (ayner E, Hebbel RP)110.7 (.)]TJ
2.1381 -1.25 Td
(Circulating activated endothelial cells in sickle cell anemia. N Engl)Tj
0 Tc T*
(J Med 1997;337:1584-90.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(12.)-875.1 (Inwald DP)110.7 (, Kirkham FJ, Peters MJ, et al. Platelet and leukocyte)]TJ
2.175 -1.25 Td
(activation in childhood sickle cell disease: association with)Tj
T*
[(nocturnal hypoxaemia. Br J Haematol 2000;1)36.8 (1)36.8 (1:474-81.)]TJ
-2.175 -1.25 Td
[(13.)-875.1 (W)79.9 (allace DJ, Linker)19.7 (-Israeli M, Hallegua D, Silverman S, Silver D,)]TJ
2.175 -1.25 Td
[(W)79.9 (eisman MH. Cytokines play an aetiopathogenetic role in)]TJ
T*
[(fibromyalgia: a hypothesis and pilot study)64.8 (. Rheumatology Oxford)]TJ
0 Tc 0 Tw T*
(2001;40:743-9.)Tj
-0.00011 Tc 0.02499 Tw -2.175 -1.25 Td
[(14.)-875.1 (Salemi S, Rethage J, )17.7 (W)79.9 (ollina U, et al. Detection of interleukin 1)]TJ
2.175 -1.25 Td
[(beta \(IL-1 beta\), IL-6, and tumor necrosis factor)19.7 (-alpha in skin of)]TJ
T*
(patients with fibromyalgia. J Rheumatol 2003;30:146-50.)Tj
-2.175 -1.25 Td
[(15.)-875.1 (Bor)17.7 (g-Stein J, Stein J. )17.7 (T)35 (rigger points and tender points. One and the)]TJ
2.175 -1.25 Td
[(same? Does injection treatment help? Rheum Dis Clin North )54.8 (Am)]TJ
0 Tc 0 Tw T*
(1996;22:305-22.)Tj
ET
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
/GS2 gs
/T1_5 8 Tf
117.48 51 Td
(Personal, non-commercial use only. The Journal of Rheumatology Copyrig\
ht \251 2004. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_6 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
16 0 obj
<>stream
8;Z\7=g#Xr#itt$j>rPEL;i\;doX4TTRJjL`XEoL$$08&:DpubjNKW#`F958#E/Z7
:`f$&qqW`DpRT77!aPoBKtUjZZjjPT+BpPK_+=nPPM[IO3QM`G0TuR")%qU;kB@B.Dlc
UHFWYQ)+_>uW&/sfX5
OM)@:WjqC'Dm@s^S\IRab=W7S?n\#eW]2P;NOa;
5(Bo%APXY/SS3AnTtf33IaT-aV*&=#AS#FaAS(nuAmZXTO-39A=[`0%\t$5dR&l9r
fn$g@!+t2QaT~>
endstream
endobj
20 0 obj
[/Indexed/DeviceRGB 255 19 0 R]
endobj
19 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
70 0 obj
<>
endobj
40 0 obj
<>
endobj
42 0 obj
<>
endobj
7 0 obj
<>
endobj
44 0 obj
<>
endobj
63 0 obj
<>
endobj
82 0 obj
<>
endobj
45 0 obj
<>
endobj
53 0 obj
<>stream
H\T}PSWO]Xmjyꋾd\uGE\|(۪uWiH>HP;$$(Uy
U"QU*ӝjWutu]kݞOv?̛;"lBTF&%&&OZnSl,y7F*1JqS#DݰEPA勲8ס1"RO8v":zYl<[fΜ,YqgGlke<Ů_`ʹ6>#ϐ5UO4KvRHMv}>2X2ͨO1Ymy}k6^oMYd+{B)-8b<R*#$a
Pt+G+}ʟ\W*U]{'lOC*z@ϠPZH8.S*~AxxF>iI(66b
|Ԝ ޛӔˮ-,}[fp?A7vv#g YT 0Y3562Wkח3^t=eaqFhؘK[{4-q2KzY)=iR.k?2isbjw:^95Ir-'K|Ѥl>
+$Ud
6+֑+%Ttf^ "
|1,tC}A /5
endstream
endobj
10 0 obj
<>
endobj
8 0 obj
<>
endobj
11 0 obj
<>stream
HTPn0t䮆$6Et%= ˃GpI@W#&WE0bQehn~grMqø5j-p\h%` h =)-fIk^(݂3.2ti~ U#eZ9eFm1fj2_/
>%ȟ l
endstream
endobj
9 0 obj
<>stream
BAAFKN+Symbol . H H alphaSymbol a &!)qK^Nk=5I^^u ֻ̱lMM& hAc_KoBr`OO=,"[,32+_" //]՟ʴ%Gggydnt|zz|yumpqqruǠS
endstream
endobj
43 0 obj
<>
endobj
58 0 obj
<>stream
H|T PTG~Ǜax odf6xZ'f@@""* 7Dn8VVФ3`\]\kIeljwv+w_ߏcろ9쎌k*cezF1qڀ!#CFld\ԟ,HQKvLiBk3q^ayMrGǕduxɒ0;5ճv=\*|j$[aJJ×K$11YFkCw6VIF"īeX:Z< P'"|R-dqPMdxL)svyc81(La`.$\1lmaEVa1̗e#0206p43H48gp gPi4!q']xsh漜}vu=1r47zgg|~ 7I3G3F"h676O5oS-YZY&[v/\ _*O%mOwBk" _gTiiz; (jGGo30 N_6#!̭xƩamvkk;+3,>PAh߸܊8SJT)D"d!YޱcPt:R B+*Hxw8h87%_ByD|
Y@L xP=eo{MC ,EccbyꦊuxS*
9Q,54h'D.٢4 bHzJ#O
>~D_Ħ W9F .Yi*91/`qPʬiWGLISDFDkz{KK.b$FMFhnJ/OS$_*?љޥ펕%&$$\/Rg_(oimKߟ=|2PސQҔYEǑrڕ _y|d=zrBBj=AG*Pn%Ȇz%^ߢpkBvp-p%t(cckTMMU-ͪ1a@ 7FAT#A?7|mݔi-^8 cOփ
h1B˵,Ń؋)02#=(وSsF?! ,=!b4/R'Lp~sؕg?bjq|rG,w!Jt=xM!Ƶ($U/>su%F{&_
C|X>,Rt
Tw;eiħHX|; JD
3z*=
oe=M豀z,fӁ@:%bt̮twz LḼ80$`+;KO
^ѱSV`u/~[HLQ
FtBX`uR+k/3][NmR2OQ!GC6`c,
9Ajյygy6rfZ.\e"1[|pp_-|{537*p}ǥ`Ų!8h;.Ԛ}sw?L@ Sy9=Ql;'v5vX`*<臧27!Jhij^ ٯ9ʊcj2Y=~7G$e"02?~Vl=Ec ݚQ~'*zU"ZPTǴ5ֳ52,{zmcL 5A;AFqqf=/Y:6.a J՛zzl]j0bMi#D2
yݩv5qfacZBXXҺ`"
*E[芨 AP@jUQb!$@\\UVVEuheu>}ΰ'vKV'3~y3
`݇9(zu6~>AQ]U+FVFq֢$KOM
؉VJ*JG=n1*́n6pN7?' Kԋs`U2L/K롹 yaX@ڈ'6_
ydR'C?
= V=s9˵S`VtaQS_k#TOS65%#Qqx6~*k3u`oGBt|_rArAGߗQa7 V&lxկOKd˖;3Cl.jpq唉&q^FD
$Rh-0]a9,ASL4/;;`NǏ8cUfG+Hp kb]+xɢ(Sb29ދ8kMNNU*XpRxXJ@0jZzQRl
=.Ա`O
\9Aֽ,J
'Irh{d"܃8kB4I>S`ahp>[{10o憭ЙJLfC3|p|yK˝2jLg
P/G(XZ$x5<$F}̥U/?3_މul0jABXH,I!ɾ 0gc] XBvʎP:(% 2.Q/fX`lS~g:֕ NWj۸oU zzޞ
uv6f;ʌ`&bIH~Igu(>:b]b(n!aV(_l#ѲMh6`#ÍG{@!.jCq1ahR8 tkRq*'8,p
fچ'o6vWy6e|nF;|{[},f2%\_,!-؆F6~#Z.l\koo03=W9AlbB}6zz}p
z
&w@ieWV+ȆD6e3?iu<$eTӚs7ɫ>Ob][8/Q]/K;ǕUTN.dtZS#=x8hsG6]J%B_Cs2QRXÀ-%^v\l'[ǒ5o{
lJ$<UQo (xh=f4QB>
vze٘6}.cODY^1F
y6k7r6BM#<* 889b<ÐG xENr䨣Ks
Ϝ2j*c:ݾt䘴~"[:> &"lkh
zA rSGVKsXZIz`"h=#{-&SKؔ,''-UZ
`'s-@n<)cg90E/VrF)1
D(>>PO%Ȍ2h%tEa1MYw,p
V@I9*$cy{= \dA&1_ޛЃV]$&ՅYJ:/'W.#;u`muk*!sIפu
c2/+Y>歟f FyVƹPAy|^8ZumOYEB
|x]:G.I0Wr eZr_ #4#tޘ1~DC~08C[EV